Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05658562 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

StatusActive, Not Recruiting
PhasePhase 1/2
Started2023-01-30
View on ClinicalTrials.gov ↗

Amendment history

2026-06-08
Study Status v17
Re-verified, no change to tracked fields
2026-02-11
Study Identification, Study Status, Outcome Measures v16
Primary completion date2025-12→2028-08
Secondary endpointsdetails revised at 3 of 13 entries
2025-12-04
2 amendments v14-v15
2 re-verifications since 2025-09-11, no change to tracked fields
2025-07-04
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v13
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 49→confirmed 46
Study sitesdetails revised at 23 of 23 sites
2025-06-04
Study Status, Contacts/Locations v12
Study sites19→23
Show 11 earlier versions
2025-02-26
Study Status, Eligibility v11
Eligibility criteria+35 characters
[...] , or antibody-drug conjugates). Within 14 days for rituximab, anti-CD3/CD20 bispecific antibody. Radiotherapy: within 14 days CAR-T therapy: within 100 day [...]
2025-01-17
Study Status v10
Re-verified, no change to tracked fields
2024-10-03
Study Status, Contacts/Locations v9
Study sites18→19
2024-08-27
Study Status, Contacts/Locations v8
Study sites16→18
2024-07-17
Study Status, Contacts/Locations v7
Study sites14→16
2023-12-15
Study Status, Contacts/Locations v6
Study sites13→14
2023-11-03
Study Status, Contacts/Locations v5
Study sites5→13
2023-08-29
Study Status, Oversight, Contacts/Locations v4
Study sites4→5
2023-02-17
Study Status, Contacts/Locations v3
Start dateestimated 2023-01→confirmed 2023-01-30
Study sitesdetails revised at 1 of 4 sites
2023-01-12
Not Yet Recruiting→Recruiting Study Status, Arms and Interventions, Eligibility, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2022-12→2023-01
Study sites0→4
Eligibility criteria+31 characters
[...] rations, radioimmunoconjugates, or antibody-drug conjugates). Within 14 days for rituximab. Radiotherapy: within 14 days CAR-T therapy: within 100 days [...]
2022-12-27
Study Status v1
Re-verified, no change to tracked fields
2022-12-13
Original filing
\[Phase I part\] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed. \[Phase II part\] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.
Trial Details
NCT Number NCT05658562
Lead Sponsor Tanabe Pharma Corporation
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 46 participants
Start Date 2023-01-30
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-09